Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoAgCide is a patented antimicrobial technology developed by WeInnovate Biosolutions, an Indian startup. It consists of a colloidal silver nanoparticle solution designed as a broad-spectrum antimicrobial additive for medical devices and environmental sanitization. The technology utilizes silver nanoparticles that exert antimicrobial activity by interacting with viral surface glycoproteins to block entry and by interfering with viral replication processes, such as the synthesis of negative-strand RNA and viral budding. NanoAgCide is primarily used for infection prevention and control, particularly to reduce hospital-acquired infections (HAIs). It is incorporated into medical devices like the SilvoGuard Foley Catheter and is used in non-alcoholic, aqueous-based hand sanitizers and surface disinfectants. The technology has received British Pharmacopeia approval and is supported by the Indian Department of Science and Technology (DST) and Department of Biotechnology (DBT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NanoAgCide.